Evan Feinberg

Evan Feinberg is the Founder and CEO of Genesis Therapeutics, an AI-driven drug discovery company he started in March 2019.13 Here's an overview of his background and accomplishments:

Education and Early Career

Evan Feinberg received his Bachelor of Science in Applied Physics from Yale University, graduating magna cum laude and Phi Beta Kappa.13 He then went on to earn his Ph.D. in Biophysics from Stanford University, where he worked in Vijay Pande's lab developing deep learning methods for molecular property prediction.12

Professional Experience

Before founding Genesis Therapeutics, Feinberg:

• Worked as a Deep Learning Consultant at Merck from April 2018 to February 20191
• Completed a Computational Biophysics Internship at Schrödinger1
• Conducted research as a Research Fellow at Memorial Sloan Kettering Cancer Center1

Genesis Therapeutics

Feinberg founded Genesis Therapeutics to accelerate drug discovery using deep learning.2 The company:

• Develops and deploys cutting-edge deep learning platforms for drug discovery1
• Originated from Feinberg's Ph.D. thesis on graph convolutional neural networks1
• Combines AI expertise with experienced drug developers who have contributed to seven approved drugs1

Scientific Contributions

Feinberg has made significant contributions to the field of AI in drug discovery:

• Co-invented novel deep neural network architectures, including PotentialNet2
• Demonstrated substantial improvements in molecular property prediction using his methods2
• Published his work in peer-reviewed journals, including ACS Central Science2

Recognition

Feinberg has received several honors for his work, including:

• Being named to the Forbes 30 Under 30 list in Healthcare in 20193
• Receiving the Blue Waters Graduate Fellowship3
• Being awarded the Applied Physics Prize from Yale University3

Evan Feinberg's expertise in deep learning, physics, and biophysics, combined with his entrepreneurial spirit, has positioned him as a leader in the field of AI-driven drug discovery.